|
Market Closed -
Nasdaq
16:00:00 2026-10-16 EDT
|
5-day change | 1st Jan Change | ||
| 2.570 USD | -3.75% |
|
-26.78% | +80.99% |
| 10-15 | Edesa Biotech, Inc. Receives FDA IND Clearance For Phase 2 Clinical Study Of EB06 In Vitiligo | CI |
| 08-19 | Edesa Biotech Launches Public Offering of Common Shares, Warrants | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
The annotated values (TR) are displayed with their "Total Return" performance (only if available).
End-of-day quotes
Sector Bio Therapeutic Drugs
| Capi. | Sales Growth | Profitability | Finances | EV / Sales | P/E | |
|---|---|---|---|---|---|---|
 | 34.72M | - | - | - | - | - |
| 65B | |||||
| 51.2B | |||||
| 51.19B | |||||
| 43.93B | |||||
| 41.96B |
- Stock Market
- Stocks
- EDSA Stock
- Charts Edesa Biotech, Inc.
- Sector Chart
Select your edition
All financial news and data tailored to specific country editions
